Reversible recurrent profound thrombocytopenia due to linezolid in a patient with multi-drug resistant tuberculosis: A case report

Medicine
Ming-Gui WangJian-Qing He

Abstract

Thrombocytopenia caused by linezolid (LZD) is common, with a reported prevalence as high as 11.8%. Platelets typically reach normal levels 7 days after LZD withdrawal. However, recurrent profound thrombocytopenia due to LZD usage and a persistent profound drop in platelet count after LZD withdrawal have not been reported. We report a case of a 75-year-old woman, who presented with recurrent profound thrombocytopenia induced by LZD treatment for multidrug-resistant tuberculosis (MDR-TB). Laboratory data and symptoms during and after LZD usage and reusage indicated severe thrombocytopenia. LZD was discontinued due to recurrent thrombocytopenia and the platelet count continued to drop for 9 days and returned to normal gradually 16 days after LZD withdrawal and supportive care including platelet transfusion. There was no recurrence of thrombocytopenia during 10 months of follow-up during treatment for MDR-TB with a regimen without LZD. Recurrent profound thrombocytopenia can happen after several doses of LZD rechallenging. Therefore, reuse of LZD should be avoided after recovery from severe thrombocytopenia due to LZD.

References

Dec 3, 1998·Antimicrobial Agents and Chemotherapy·S M SwaneyD L Shinabarger
Jan 11, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Mary C BirminghamJerome J Schentag
Mar 28, 2003·The Annals of Pharmacotherapy·Wendy B BernsteinAnthony J Barile
Dec 17, 2008·Antimicrobial Agents and Chemotherapy·K N WilliamsE Nuermberger
Feb 13, 2010·The Journal of Antimicrobial Chemotherapy·Holly A AngerShama D Ahuja
Apr 13, 2012·The European Respiratory Journal·Giovanni SotgiuGiovanni Battista Migliori
Oct 19, 2012·The New England Journal of Medicine·Myungsun LeeClifton E Barry
Dec 1, 2012·Current Therapeutic Research, Clinical and Experimental·Chao ChenLiang Ma
Jun 11, 2014·International Journal of Clinical Pharmacy·Ryuichi HiranoMotoki Ohnishi
Sep 23, 2014·The European Respiratory Journal·Shenjie TangZhanjun Zhang
Mar 24, 2016·Japanese Journal of Infectious Diseases·Lina YiSatoshi Mitarai
Jun 21, 2016·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Yuki HanaiTakashi Yoshio
Feb 12, 2017·British Journal of Clinical Pharmacology·Yasuhiro TsujiYoshihiro Yamamoto
Mar 24, 2017·The European Respiratory Journal·Dennis FalzonKarin Weyer

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy

Related Concepts

Related Feeds

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Related Papers

Medical Journal, Armed Forces India
P L PrasadK Chand
The Lancet Infectious Diseases
Helen CoxEric Goemaere
The Lancet Infectious Diseases
Kwok-Chiu ChangCharles L Daley
American Journal of Therapeutics
Venugopalan Y VishnuVivek Lal
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease
W W YewK H Wen
© 2022 Meta ULC. All rights reserved